Glucocorticoid-Induced Leucine Zipper Protein and Yeast-Extracted Compound Alleviate Colitis and Reduce Fungal Dysbiosis
Biomolecules · 2024
DOI: 10.3390/biom14101321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Marco Gentili und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Pharmacology Division, University of Perugia, 06132 Perugia, Italy. Hauptthemen laut MEDLINE: Dysbiosis, Colitis, Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vini di Batasiolo S.p.a., Vini di Batasiolo S.p.A.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD) have a complex, poorly understood pathogenesis and lack long-lasting effective treatments. Recent research suggests that intestinal fungal dysbiosis may play a role in IBD development. This study investigates the effects of the glucocorticoid-induced leucine zipper protein (GILZp)”, known for its protective role in gut mucosa, and a yeast extract (Py) with prebiotic properties, either alone or combined, in DSS-induced colitis. Both treatments alleviated symptoms via overlapping or distinct mechanisms. In particular, they reduced the transcription levels of pro-inflammatory cytokines IL-1β and TNF-α, as well as the expression of the tight junction protein Claudin-2. Additionally, GILZp increased MUC2 transcription, while Py reduced IL-12p40 and IL-6 levels. Notably, both treatments were effective in restoring the intestinal burden of clinically important Candida and related species. Intestinal mycobiome analysis revealed that they were able to reduce colitis-associated fungal dysbiosis, and this effect was mainly the result of a decreased abundance of the Meyerozima genus, which was dominant in colitic mice. Overall, our results suggest that combined treatment regimens with GILZp and Py could represent a new strategy for the treatment of IBD by targeting multiple mechanisms, including the fungal dysbiosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Pharmacology Division, University of Perugia, 06132 Perugia, Italy.
- Department of Medicine and Surgery, Medical Microbiology Division, University of Perugia, 06132 Perugia, Italy.
- Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
- Lesaffre Institute of Science & Technology, Lesaffre International, 59700 Marcq-en-Baroeul, France.
ORCID-Profile: Marco Gentili, Samuele Sabbatini, Luigi Cari, Antonella Mencacci, Nathalie Ballet, Carlo Riccardi, Simona Ronchetti, Claudia Monari
Förderung
- Vini di Batasiolo S.p.a.
- Vini di Batasiolo S.p.A
Zitieren
APA
Gentili, M., Sabbatini, S., Nunzi, E., Lusenti, E., Cari, L., Mencacci, A., Ballet, N., Migliorati, G., Riccardi, C., Ronchetti, S., & Monari, C. (2024). Glucocorticoid-Induced Leucine Zipper Protein and Yeast-Extracted Compound Alleviate Colitis and Reduce Fungal Dysbiosis. Biomolecules. https://doi.org/10.3390/biom14101321
Vancouver
Gentili M, Sabbatini S, Nunzi E, Lusenti E, Cari L, Mencacci A, et al. Glucocorticoid-Induced Leucine Zipper Protein and Yeast-Extracted Compound Alleviate Colitis and Reduce Fungal Dysbiosis. Biomolecules. 2024. doi:10.3390/biom14101321
BibTeX
@article{Gentili2024,
author = {Gentili, Marco and Sabbatini, Samuele and Nunzi, Emilia and Lusenti, Eleonora and Cari, Luigi and Mencacci, Antonella and Ballet, Nathalie and Migliorati, Graziella and Riccardi, Carlo and Ronchetti, Simona and Monari, Claudia},
title = {Glucocorticoid-Induced Leucine Zipper Protein and Yeast-Extracted Compound Alleviate Colitis and Reduce Fungal Dysbiosis},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14101321}
}
EUVIMED